749223-61-8 Usage
General Description
1H-Indazol-5-amine,6-methoxy-(9CI) is a chemical compound that belongs to the class of organic compounds known as indazoles, which are aromatic heterocyclic compounds containing a benzene and a pyrazole ring fused together. The "6-methoxy-" refers to a methoxy group, a common functional group composed of a methyl group bound to an oxygen atom, attached to the 6th carbon atom in the indazole ring. The "5-amine" refers to an amino group attached to the 5th carbon in the ring. As it's a compound found within the context of synthetic processes, it's often used in the field of organic chemistry for the synthesis of more complex molecules. The specific properties, such as solubility, melting point, or boiling point, of this chemical can vary and are often determined by additional functional groups or structural attributes.
Check Digit Verification of cas no
The CAS Registry Mumber 749223-61-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,9,2,2 and 3 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 749223-61:
(8*7)+(7*4)+(6*9)+(5*2)+(4*2)+(3*3)+(2*6)+(1*1)=178
178 % 10 = 8
So 749223-61-8 is a valid CAS Registry Number.
749223-61-8Relevant articles and documents
COMPOUND SERVING AS IRAK INHIBITOR
-
Paragraph 0146; 0149, (2021/10/07)
The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
-
, (2012/02/01)
Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
